Flexible Dosing Lets You Individualize Treatment

Vivelle-Dot® Delivers Therapeutic Estrogen Levels Across a Range of Doses

Vivelle-Dot offers the flexibility of 5 available dosage strengths to suit the needs of your individual patients.

Vivelle-Dot® delivers therapeutic estrogen levels across a range of doses

Patches may not be shown at actual size.
†Vivelle-Dot 0.025 mg/day is indicated for the prevention of postmenopausal osteoporosis only

Did you find this page helpful? Yes No

Vivelle-Dot has 4 Indications for Menopause

Vivelle-Dot, the #1 prescribed transdermal estrogen therapy, is FDA approved for 4 indications.
Learn more

Great Design with DOT Matrix® Technology

Delivery Optimized Thermodynamics (DOT) Matrix® Technology provides multiple benefits.
Learn more

Order Samples & Support Materials

Extensive patient support in and out of the office.
Learn more
  1. Vivelle-Dot (estradiol transdermal system) [prescribing information]. Novartis Pharmaceuticals Corporation; August 2004.

The information contained within this Web site is appropriate for U.S. healthcare professionals only. A visit to this site should not replace a visit to your doctor.
Copyright © 2011 Novogyne Pharmaceuticals. All rights reserved5/11 VVD-1051503

X
Tell A Colleague

Share information about Vivelle-Dot® by e-mailing this Web site to a colleague.

After clicking the "Send" button below, your colleague will receive an e-mail containing a link to this Web site.
* Required Fields
Continue Cancel
Leaving the Vivelle-Dot® Web Site

Continue Cancel